公开(公告)号：US20070060635A1

公开(公告)日：2007-03-15

申请号：US11503607

申请日：2006-08-14

申请人： Samuel Broder ,  Kenneth Duchin ,  Sami Selim

发明人： Samuel Broder ,  Kenneth Duchin ,  Sami Selim

IPC分类号： A61K31/337

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/337 ,  A61K38/13 ,  Y02A50/411 ,  A61K2300/00

摘要： A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

摘要翻译： 在口服给药药物活性的靶剂，特别是表现出差的或不一致的口服生物利用度（例如紫杉醇，多西紫杉醇或依托泊苷）的抗肿瘤剂或抗肿瘤药物时，增加生物利用度的方法包括向哺乳动物患者口服共同施用 目标剂和口服生物利用度增加剂（例如环孢菌素A，环孢菌素D，环孢菌素F或酮康唑）。 增强剂可以在0.5-24小时口服给药。 在一次或多次剂量的目标试剂口服给药之前，基本上同时与目标试剂或两者在目标试剂之前和基本上同时进行。 治疗患有对具有差的口服生物利用度的靶因子起反应的疾病的哺乳动物患者的方法以及含有这些靶因子的口服剂型，含有生物利用度增强剂和靶剂的组合口服剂型和含有增强剂和靶剂剂型的试剂盒 并且还公开了其共同给药的给药信息。

公开(公告)号：US20050238634A1

公开(公告)日：2005-10-27

申请号：US11105081

申请日：2005-04-13

申请人： Samuel Broder ,  Kenneth Duchin ,  Sami Selim

发明人： Samuel Broder ,  Kenneth Duchin ,  Sami Selim

IPC分类号： A61K47/06 ,  A61K9/00 ,  A61K31/00 ,  A61K31/135 ,  A61K31/337 ,  A61K38/04 ,  A61K38/08 ,  A61K38/13 ,  A61K38/54 ,  A61K45/06 ,  A61K47/22 ,  A61P13/12 ,  A61P31/12 ,  A61P35/00

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/337 ,  A61K38/13 ,  Y02A50/411 ,  A61K2300/00

摘要： A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent. A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

摘要翻译： 在口服给药药物活性的靶剂，特别是表现出差的或不一致的口服生物利用度（例如紫杉醇，多西紫杉醇或依托泊苷）的抗肿瘤剂或抗肿瘤药物时，增加生物利用度的方法包括向哺乳动物患者口服共同施用 目标剂和口服生物利用度增加剂（例如环孢菌素A，环孢菌素D，环孢菌素F或酮康唑）。 增强剂可以在0.5-24小时口服给药。 在一次或多次剂量的目标试剂口服给药之前，基本上同时与目标试剂或两者在目标试剂之前和基本上同时进行。 治疗患有对具有差的口服生物利用度的靶因子起反应的疾病的哺乳动物患者的方法以及含有这些靶因子的口服剂型，含有生物利用度增强剂和靶剂的组合口服剂型和含有增强剂和靶剂剂型的试剂盒 并且还公开了其共同给药的给药信息。